IMAB Wutah pendapatan triwulanan I-Mab Biopharma

Simbol lan logo merek i-mabbiopharma.com (IMAB)

I-Mab combines global oncological expertise with a Western approach to innovation, attracting talent through generous stock options. This establishes a foundation for owning unique patents and maintaining pricing power. The change in quarterly sales volume illustrates the growth dynamics, where the 0.00 metric confirms the current level. Meanwhile, management strictly controls the burn rate during the period of restructuring and US clinical trials.

i-mabbiopharma.com (IMAB) - Tingkat wutah pendapatan sajrone kuartal saka 04.07.2022 nganti 30.10.2025

I-Mab Inc. (IMAB) - rincian metrik lan laporan keuangan

- kuotasi saiki lan rata-rata prakiraan nilai:
Analisis umum perusahaan:i-mabbiopharma.com (IMAB)
Barang unggulan I-Mab Biopharma Co., Ltd.

This metric measures the daily rate of change in quarterly revenue, revealing the actual speed of capital inflow by stripping out random fluctuations. For I-Mab (IMAB), this calculation reflects the efficiency of exercising antibody rights with Western partners without incurring infrastructure costs. By analyzing the quarterly sales growth trend, an investor can discern the true frequency of license fee receipts. A stable trend here confirms the resilience of the model and protects capital from a hidden business slowdown.

Pesaing utama

INCY - Wutah pendapatan kuartal marang kuartal|Owah-owahan pendapatan dibandhingake kuartal kepungkur HUTCHMED (HCM)|NUVB: Wutah pendapatan triwulanan|Owah-owahan pendapatan dibandhingake kuartal kepungkur Day One Bio DAWN|Wutah dodolan triwulanan MNPR|Tingkat wutah pendapatan sajrone kuartal Inhibrx Biosciences INBX|Wutah dodolan triwulanan FENC (Fennec Pharmaceuticals)|HRTX (Heron Therapeutics Inc) - Tambahing pendapatan triwulanan|Nuvectis Pharma, Inc. - Wutah dodolan triwulanan|Owah-owahan dodolan kuartal marang kuartal CHRS (Coherus BioSciences)|Corbus Pharma - Wutah pendapatan triwulanan|Tambahing pendapatan triwulanan CRDF (cardiffoncology.com)|BYSI: Wutah pendapatan triwulanan|Tingkat wutah pendapatan sajrone kuartal BioAtla Corp (BCAB)|Wutah pendapatan kuartal marang kuartal Lixte Biotechnology Holdings, Inc.|CTXR: Tambahing pendapatan triwulanan|Wutah pendapatan triwulanan CLRB|Wutah pendapatan triwulanan BioLineRx Corporation (BLRX)|Wutah pendapatan kuartal marang kuartal Can-Fite BioPharma, Ltd. CANF|APRE (aprea.com) - Dinamika pendapatan kuartal marang kuartal|KZIA: Wutah dodolan triwulanan|Tingkat wutah pendapatan sajrone kuartal Silexion Therapeutics|NuCana plc (NCNA) - Wutah pendapatan kuartal marang kuartal|Wutah dodolan triwulanan Chimerix, Inc|Wutah dodolan triwulanan CYCC|Wutah dodolan triwulanan G1 Therapeutics (GTHX)|Wutah pendapatan kuartal marang kuartal Kronos Bio Corporation (KRON)|Kintara - Wutah dodolan kuartal marang kuartal|Oncternal Therapeutics, Inc. - Wutah dodolan triwulanan|Owah-owahan dodolan kuartal marang kuartal PRTG (Portage)